Latest Blockchain news from around the world

Novo Nordisk’s controlling shareholder to purchase Catalent for $16.5 billion

0



The controlling shareholder of weight-loss drug maker Novo Nordisk on Monday mentioned it’s shopping for a supplier of drug manufacturing for $16.5 billion.

Novo Holdings, the controlling shareholder of Novo Nordisk
NVO,
-1.80%,
mentioned it’s shopping for Catalent
CTLT,
+2.67%
for $16.5 billion in money, or $63.50 per Catalent share, a 16.5% premium to Friday’s shut.

Catalent inventory rose 13% in premarket commerce to $61.48.

The deal is a 39% premium to Catalent’s shut earlier than it introduced a strategic evaluation.

The deal will see Novo promote three fill-finish websites to Novo Nordisk shortly after the deal closes. Novo Nordisk has been struggling to satisfy demand for its widespread injectable weight-loss medication.

Catalent has greater than 50 websites globally.

Catalent investor Elliott Funding Administration mentioned it helps the deal.

Novo Holdings had property of €108 billion on the finish of 2022.

Leave A Reply

Your email address will not be published.